MedTrace Logo

Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis

NCT00361283 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2012-05-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to test whether atorvastatin (also known as Lipitor) has anti-inflammatory effects in people with no known heart disease or high cholesterol. We also are investigating whether or not genetic differences between people plays a role in the drug response.

Conditions

Interventions

DRUG

Atorvastatin

atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks

Sponsors & Collaborators

  • American Heart Association

    collaborator OTHER

  • American College of Clinical Pharmacy

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Reginald Frye, PharmD, PhD · University of Florida College of Pharmacy

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2008-12-31
Completion
2009-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00361283 on ClinicalTrials.gov